

Hideki Fujii

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7787862/publications.pdf>

Version: 2024-02-01

136
papers

6,023
citations

101543

36
h-index

82547

72
g-index

145
all docs

145
docs citations

145
times ranked

7117
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 908-917.e11.	4.4	57
2	lpragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , 2022, 6, 120-132.	4.3	60
3	<scp>MRI</scp>â€Based Quantitative R2[*] Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 111-125.	3.4	13
4	The Albumin-bilirubin Score Detects Changes in the Liver Function during Treatment for Budd-Chiari Syndrome: A Retrospective Observational Study. <i>Internal Medicine</i> , 2022, 61, 959-967.	0.7	1
5	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter caseâ€control study. <i>Journal of Gastroenterology</i> , 2022, 57, 19-29.	5.1	8
6	Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunctionâ€associated fatty liver disease. <i>Liver International</i> , 2022, , .	3.9	12
7	Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. <i>Scientific Reports</i> , 2022, 12, 105.	3.3	3
8	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 186-195.	7.3	9
9	Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. <i>Hepatology Communications</i> , 2022, 6, 2090-2104.	4.3	15
10	Serum Macâ€2 binding protein level predicts the development of liverâ€related events and colorectal cancer in patients with NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1527-1536.	4.3	3
11	Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicenter study by the Japanese Red Cross Liver Study Group. <i>Journal of Viral Hepatitis</i> , 2022, , .	2.0	0
12	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	4.3	17
13	<scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>directâ€acting antiviral</scp> therapy. <i>JGH Open</i> , 2022, 6, 487-495.	1.6	0
14	COVID-19 reduced the detection of lung cancer in first-time visitors, but not in repeated visitors in annual lung cancer screening.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24041-e24041.	1.6	0
15	Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas. <i>Oncology</i> , 2021, 99, 186-191.	1.9	13
16	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021, 5, 559-572.	4.3	25
17	Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. <i>Internal Medicine</i> , 2021, 60, 3441-3445.	0.7	2
18	A mask-based infection control method for screening endoscopy may prevent SARS-CoV-2 transmission and relieve staff anxiety. <i>SAGE Open Medicine</i> , 2021, 9, 2050312121110470.	1.8	2

#	ARTICLE	IF	CITATIONS
19	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021, 11, 143.	2.4	22
20	Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2021, 51, 554-569.	3.4	28
21	Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2021, 51, 1044-1057.	3.4	9
22	Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. <i>JGH Open</i> , 2021, 5, 801-808.	1.6	2
23	Anti-fibrotic treatments for chronic liver diseases: The present and the future. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 413-424.	8.9	23
24	The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. <i>Scientific Reports</i> , 2021, 11, 13844.	3.3	14
25	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1451-1458.	1.6	10
26	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 951-963.	5.1	114
27	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021, 51, 1013-1025.	3.4	58
28	Direct-Acting Antivirals Reduce the Risk of Tumor Progression of Hepatocellular Carcinoma after Curative Treatment. <i>Journal of Viral Hepatitis</i> , 2021, , .	2.0	2
29	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2021, 177, 391-403.	2.9	12
30	Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. <i>Journal of Gastroenterology</i> , 2021, 56, 1045-1061.	5.1	18
31	IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism. <i>Cells</i> , 2021, 10, 3513.	4.1	10
32	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2020, 55, 428-440.	5.1	50
33	Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 217.	2.0	19
34	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020, 10, 912.	2.6	15
35	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	1.3	17
36	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Metabolomic/lipidomicâ€based analysis of plasma to diagnose hepatocellular ballooning in patients with nonâ€alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 955-965.	3.4	12
38	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4039.	4.1	35
39	The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3863.	4.1	118
40	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1907.	4.1	42
41	Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. <i>Cancers</i> , 2020, 12, 754.	3.7	18
42	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and nonâ€invasive tests for the diagnosis of advanced liver fibrosis in patients with nonâ€alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 682-692.	3.4	32
43	Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3392.	3.3	46
44	Idiopathic hypereosinophilic syndrome with formation of multiple liver mass lesions. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 834-838.	0.8	1
45	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 953-967.	1.8	28
46	TGF-Î²1-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2020, 73, 882-895.	3.7	24
47	Diagnostic accuracy of FibroScanâ€AST score to identify nonâ€alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with nonâ€alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020, 50, 831-839.	3.4	32
48	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1926-1933.	3.9	14
49	VI. Screening High-risk Non-alcoholic Fatty Liver Disease (NAFLD). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 47-55.	0.0	0
50	A case of ectopic hepatocellular carcinoma originating from the retroperitoneum. <i>Acta Hepatologica Japonica</i> , 2020, 61, 597-606.	0.1	0
51	Last crusade against HCV: Directâ€acting antiviral treatment for marginalized populations. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1501-1501.	2.0	0
52	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <i>Biomedical Reports</i> , 2019, 11, 63-69.	2.0	1
53	Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 5149-5156.	1.1	57
54	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1626-1632.	2.8	19

#	ARTICLE	IF	CITATIONS
55	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 1136-1146.	3.4	24
56	Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 355-360.	0.8	7
57	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 389-398.	8.1	616
58	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	3.4	19
59	Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. <i>Hepatology</i> , 2019, 70, 2035-2046.	7.3	83
60	A case series of five patients with hepatic sarcoidosis diagnosed by liver biopsy. <i>Acta Hepatologica Japonica</i> , 2019, 60, 405-413.	0.1	1
61	<scp>HOMA-IR</scp>: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	2.8	67
62	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1411-1416.	2.8	6
63	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. <i>Hepatology Research</i> , 2018, 48, 746-756.	3.4	11
64	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1795-1803.	2.8	34
65	Sequential therapy involving an early switch from entecavir to pegylated interferon- α in Japanese patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, 459-468.	3.4	4
66	A Bile Duct Stone Formation around a Fish Bone as a Nidus after Pancreatoduodenectomy. <i>Case Reports in Gastroenterology</i> , 2018, 12, 69-75.	0.6	8
67	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , 2018, 48, E252-E262.	3.4	37
68	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018, 53, 181-196.	5.1	61
69	Changes in plasma interleukin-8 and tumor necrosis factor- α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 857-864.	2.3	6
70	Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2018, 113, 1409-1411.	0.4	22
71	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434.	3.3	32
72	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	5.1	68

#	ARTICLE	IF	CITATIONS
73	Magnetic resonance elastography increases usefulness and safety of noninvasive screening for esophageal varices. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2022-2028.	2.8	30
74	Identification of core gene networks and hub genes associated with progression of nonalcoholic fatty liver disease by RNA sequencing. <i>Hepatology Research</i> , 2017, 47, 1445-1458.	3.4	23
75	Use of Mac2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. <i>Hepatology Communications</i> , 2017, 1, 780-791.	4.3	38
76	Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 434.	4.1	20
77	Late-onset severe biliary bleeding after endoscopic pigtail plastic stent insertion. <i>World Journal of Gastroenterology</i> , 2017, 23, 735.	3.3	7
78	Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. <i>World Journal of Hepatology</i> , 2017, 9, 1064.	2.0	9
79	Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. <i>BMC Infectious Diseases</i> , 2016, 16, 410.	2.9	18
80	The Alcohol Use Disorders Identification Test for Consumption (AUDIT-C) is more useful than pre-existing laboratory tests for predicting hazardous drinking: a cross-sectional study. <i>BMC Public Health</i> , 2016, 16, 379.	2.9	38
81	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 484-485.	4.4	0
82	Hepatitis B Virus and DNA Stimulation Trigger a Rapid Innate Immune Response through NF- κ B. <i>Journal of Immunology</i> , 2016, 197, 630-643.	0.8	38
83	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016, 51, 586-596.	5.1	49
84	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	1.3	628
85	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. <i>PLoS ONE</i> , 2016, 11, e0146337.	2.5	135
86	Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of <i>Helicobacter pylori</i> . <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 550.	1.1	31
87	Decreasing Liver Stiffness Following Pericardiectomy for Constrictive Pericarditis. <i>Internal Medicine</i> , 2015, 54, 2079-2080.	0.7	1
88	A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. <i>Hepatology</i> , 2015, 62, 1433-1443.	7.3	61
89	Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. <i>Annals of Hepatology</i> , 2015, 14, 28-35.	1.5	4
90	Viral Hepatitis: Past and Future of HBV and HDV. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021345-a021345.	6.2	38

#	ARTICLE	IF	CITATIONS
91	Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1502-1509.e5.	4.4	44
92	Cytoglobin Deficiency Promotes Liver Cancer Development from Hepatosteatosi through Activation of the Oxidative Stress Pathway. <i>American Journal of Pathology</i> , 2015, 185, 1045-1060.	3.8	46
93	Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 63, 494-502.	3.7	71
94	Screening of nonalcoholic fatty liver disease in patients with coronary heart disease by transient elastography: proceed with caution. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 75-76.	1.9	0
95	Insulin Resistance Correlated With the Severity of Liver Histology in Japanese NAFLD Patients. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 169-170.	2.2	8
96	Are Platelets Count Useful for Detecting the Grade of Steatosis?. <i>Hepatitis Monthly</i> , 2015, 15, e28957.	0.2	2
97	Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. <i>Hepatology Research</i> , 2014, 44, E499-502.	3.4	19
98	The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 60, 1792-1792.	7.3	26
99	Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1715-1721.	2.8	23
100	Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver. <i>Laboratory Investigation</i> , 2014, 94, 192-207.	3.7	48
101	Positioning of ¹⁸ F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1722-1727.	2.8	14
102	Fibrogenesis in alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 8048.	3.3	33
103	Re: "Acoustic Radiation Force Impulse and Supersonic Shear Imaging Versus Transient Elastography for Liver Fibrosis Assessment". <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 1918.	1.5	0
104	Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated interferon and ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 201-207.	2.8	13
105	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1477-1484.	5.1	119
106	Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. <i>Journal of Human Genetics</i> , 2014, 59, 241-246.	2.3	18
107	Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2014, 47, 1138-1139.	1.9	9
108	Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. <i>Journal of Gastroenterology</i> , 2013, 48, 1051-1060.	5.1	37

#	ARTICLE	IF	CITATIONS
109	Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the noninvasive assessment of liver fibrosis in chronic liver diseases. <i>Hepatology Research</i> , 2013, 43, 735-742.	3.4	20
110	Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. <i>Proteomics - Clinical Applications</i> , 2013, 7, 648-656.	1.6	51
111	Modification of a simple clinical scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2013, 4, 651-658.	2.4	11
112	Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2013, 8, e66328.	2.5	59
113	Effect of Caffeine-Containing Beverage Consumption on Serum Alanine Aminotransferase Levels in Patients with Chronic Hepatitis C Virus Infection: A Hospital-Based Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83382.	2.5	6
114	Real-time PCR assays for hepatitis C virus RNA (genotype 1) is useful for evaluating virological response to the treatment with peginterferon-alpha2b and ribavirin. <i>Osaka City Medical Journal</i> , 2013, 59, 79-89.	0.4	0
115	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. <i>Gut</i> , 2012, 61, 1600-1609.	12.1	212
116	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. <i>BMC Gastroenterology</i> , 2012, 12, 2.	2.0	295
117	Inflammation and fibrogenesis in steatohepatitis. <i>Journal of Gastroenterology</i> , 2012, 47, 215-225.	5.1	123
118	Thrombocytopenia is more severe in patients with chronic hepatitis C than in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2012, 47, 606-607.	5.1	10
119	High prevalence of hepatitis C virus infection in Airin district, Osaka, Japan: A hospital-based study of 1162 patients. <i>Hepatology Research</i> , 2011, 41, 731-737.	3.4	3
120	Close correlation of liver stiffness with collagen deposition and presence of myofibroblasts in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2011, 41, 897-903.	3.4	16
121	Favorable factors for retreatment with pegylated interferon α 2a plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. <i>Hepatology Research</i> , 2011, 41, 1169-1177.	3.4	4
122	Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2011, 46, 350-358.	5.1	83
123	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011, 46, 257-268.	5.1	185
124	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011, 46, 1300-1306.	5.1	108
125	Serum Ferritin Is a Clinical Biomarker in Japanese Patients with Nonalcoholic Steatohepatitis (NASH) Independent of HFE Gene Mutation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 808-814.	2.3	71
126	Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. <i>BMC Medical Genetics</i> , 2010, 11, 172.	2.1	140

#	ARTICLE	IF	CITATIONS
127	Nonalcoholic Fatty Liver Disease: US-based Acoustic Radiation Force Impulse Elastography. <i>Radiology</i> , 2010, 256, 640-647.	7.3	323
128	Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2010, 40, 693-700.	3.4	30
129	Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2009, 44, 608-614.	5.1	38
130	Laparoscopic observation of 2 cases of nodular regenerative hyperplasia of the liver. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 171-173.	1.0	1
131	Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. <i>Journal of Gastroenterology</i> , 2007, 42, 375-381.	5.1	84
132	Identification of vitamin A-free cells in a stellate cell-enriched fraction of normal rat liver as myofibroblasts. <i>Histochemistry and Cell Biology</i> , 2007, 127, 161-174.	1.7	29
133	A murine model of NKT cell-mediated liver injury induced by alpha-galactosylceramide/d-galactosamine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 663-673.	2.8	20
134	Serum Ferritin Is Associated With Visceral Fat Area and Subcutaneous Fat Area. <i>Diabetes Care</i> , 2005, 28, 2486-2491.	8.6	126
135	Localization of lymphocyte apoptosis in murine lymphoid tissues after stimulation of natural killer T cells with alpha-galactosylceramide.. <i>Archives of Histology and Cytology</i> , 2003, 66, 397-406.	0.2	1
136	Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. <i>JGH Open</i> , 0, , .	1.6	1